|Day Low/High||8.21 / 8.65|
|52 Wk Low/High||7.33 / 48.05|
Upside - +72% (to be acquired by Pfizer for $148.50/shr in cash plus 0.5/shr of new publicly traded company valued at $11.6B) - +37% (earnings, guidance) - +20% (to be acquired by Prologis for $61.68/shr) - +20% (awarded order of 10K electric trucks...
Here's what it's going to take to turn the charts positive.
Investment experts pick their favorites in the sector for 2022, ranging from diagnostics to medical devices and medical marijuana to drug development.
Brick and Mortar strikes back.
I'm focusing on the active consumers and subscription plans as it gives us a view of the future.
Avoid the long side of GDRX until we see evidence of a durable bottom.
Have the charts improved over the last few months?
We can still look forward to that always elusive 'follow through' day for the Nasdaq.
IPOs in recent months have done extremely well -- not so GDRX.
Traders have to take the extra step to understand the underlying company and sector before jumping into a position.
The good news is that my trade offered an opportunity for a quick profit. The bad news is it didn't last very long.
Trading volume was low enough Wednesday to indicate a lack of conviction, or conviction that did not spread across enough managers to truly change the narrative.
Definitely put this one on the highly speculative side.
GDRX will not stay in a tight range for long.